Parastou Foroutan1, Christopher L. Cubitt2, 3, Jillaina L. Menth3, Damon Reed2, 4, Marilyn M. Bui2, David L. Morse1, Douglas G. Letson4, Daniel Sullivan2, Robert J. Gillies1, Gary V. Martinez1
1Imaging, H. Lee Moffitt Cancer Center, Tampa, FL, United States; 2Experimental Therapeutics Program, H. Lee Moffitt Cancer Center, Tampa, FL, United States; 3Translational Research Lab, H. Lee Moffitt Cancer Center, Tampa, FL, United States; 4Sarcoma Program, H. Lee Moffitt Cancer Center, Tampa, FL, United States
Using MRI at 7T, the therapeutic effect of Dasatinib and Triciribine were evaluated in Ewings Sarcoma mouse xenografts. Following treatments, tumor growth increased significantly for ctrl and Tri compared to Das and combination groups. The two responsive groups also showed significant increases in ADC as well as altered skewness and kurtosis while the Ctrl and Tri remained relatively constant. Interestingly, correlation of T2 intensity, ADC and volume suggested that alterations in T2, in addition to ADC, may serve as an early indicator of treatment response. In agreement, histology demonstrated significantly higher necrosis and lower cell viability in Das and Comb.